These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37950501)

  • 1. Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study.
    Kang DH; Kwon SH; Lew BL
    J Dermatol; 2024 Mar; 51(3):e63-e65. PubMed ID: 37950501
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.
    Guédon C; Tauber M; Linder C; Paul C; Shourick J
    Ann Dermatol Venereol; 2023 Sep; 150(3):215-216. PubMed ID: 37598014
    [No Abstract]   [Full Text] [Related]  

  • 3. Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab.
    Cioppa V; Lazzeri L; Carraro A; De Piano E; Falcinelli F; Galluzzo M; Pallotta S; De Pità O; Russo F
    Dermatitis; 2024; 35(S1):S107-S108. PubMed ID: 37594754
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study.
    Keow S; Abu-Hilal M
    J Am Acad Dermatol; 2024 Oct; 91(4):734-735. PubMed ID: 38857764
    [No Abstract]   [Full Text] [Related]  

  • 5. Dupilumab therapy in children aged 2-12 years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study.
    Zhou B; Peng C; Cao Q; Wang J; Chen X; Li J
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e35-e38. PubMed ID: 37565387
    [No Abstract]   [Full Text] [Related]  

  • 6. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
    Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Gurioli C; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Esposito M; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
    J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e384-e388. PubMed ID: 36225088
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
    Mastorino L; Gelato F; Richiardi I; Cavaliere G; Quaglino P; Ortoncelli M; Ribero S
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):e691-e692. PubMed ID: 36688263
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study.
    Pezzolo E; Rossi M; Caroppo F; Bianchelli T; Belloni Fortina A; Giacchetti A; Calzavara Pinton P; Naldi L
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e757-e759. PubMed ID: 36662631
    [No Abstract]   [Full Text] [Related]  

  • 9. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
    Paller AS; Siegfried EC; Simpson EL; Cork MJ; Sidbury R; Chen IH; Khokhar FA; Xiao J; Dubost-Brama A; Bansal A
    Am J Clin Dermatol; 2024 Jul; 25(4):655-668. PubMed ID: 38743155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab for moderate-severe atopic dermatitis: a real-world, single-center retrospective study of 122 patients in the United States.
    Emmerich VK; Williams JA; Hrin ML; Feldman SR; Strowd LC
    Int J Dermatol; 2024 Apr; 63(4):524-525. PubMed ID: 38093434
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China.
    Deng S; Wang H; Chen Q; Chen X; Song X; Chen S; Kong M; Song Z
    Arch Dermatol Res; 2024 May; 316(6):304. PubMed ID: 38819652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.
    Achten R; Thijs J; van Luijk C; Knol E; Delemarre E; de Graaf M; Bakker D; de Boer J; van Wijk F; de Bruin-Weller M
    Clin Exp Allergy; 2023 Feb; 53(2):239-243. PubMed ID: 36550628
    [No Abstract]   [Full Text] [Related]  

  • 14. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol; 2023 Jul; 189(2):e39. PubMed ID: 37459131
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.
    Sánchez-García V; Navarro-Triviño FJ; Silvestre JF
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1426-e1429. PubMed ID: 37458506
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis.
    Cunningham KN; Alsukait S; Cohen SR; Learned C; Gao DX; Kachuk C; Dumont N; Zipeto A; Rosmarin D
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e765-e767. PubMed ID: 36688247
    [No Abstract]   [Full Text] [Related]  

  • 20. Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China.
    Song X; Liu B; Luan T; Liao S; Tan Y; Peng C; Zhao Z
    Allergy; 2023 Jun; 78(6):1696-1699. PubMed ID: 36708064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.